Therapeutic Effects of Fenofibrate on Blood Serum Lipid in Type II Diabetic Patients in El-beida, Libya

Abstract

The risks of dyslipidemia and cardiovascular diseases are well known to be increased in diabetic patients. Moreover, the therapeutic response of fenofibrate drug on blood serum lipid is also known. However, previous studies did not compare the outcomes of fenofibrate on blood serum levels in patients with type II diabetes mellitus with non-diabetic patients. The purpose of this study was to analyze the outcomes of fenofibrate on blood serum lipid profiles in hyperlipidemic patients with type II diabetes mellitus compared to hyperlipidemic patients without diabetes mellitus. This study was conducted on 40 type II diabetic patients and 30 non-diabetic patients. Their ages varied 30-55 years and all of them were hyperlipidemic. Blood serum lipid levels were measured before and once treatment at 1, 2, and 4 months. It was found that the levels of S. Total sterol and S. LDL-C were less in diabetic patients than in non-diabetic patients once they were exploited the different doses of fenofibrate, whereas the changes in S. HDL-C and S. triglyceride were nearly similar in each. Furthermore, it was noticed that just about the same responses of S. Total sterol and S. LDL-C reduction were achieved in diabetic patients once they were using a higher dose than that used for non-diabetic patients. Thus, higher doses of fenofibrate are required to reduce blood serum lipid levels in diabetic patients as compared to non-diabetic patients.